Finance

Lists
Q2 2026 earnings • released • EPS beat +11.97% • Revenue beat +6.73%
See results
AMG:ETR
Amgen Inc
€350.95
+0.37%
(+1.30) 1D
Aug 7, 5:36:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for AMG...
Open
€351.45
High
€352.20
Low
€348.35
Mkt. cap
222.17B
Avg. vol.
479.00
Volume
618.00
52-wk high
€359.75
52-wk low
€230.00
No. of employees
32K
Open
€351.45
High
€352.20
Low
€348.35
Mkt. cap
222.17B
Avg. vol.
479.00
Volume
618.00
52-wk high
€359.75
52-wk low
€230.00
No. of employees
32K
News stories
From sources across the web
Profile
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia
About Amgen Inc
CEORobert A. Bradway
Employees31.5K
FoundedApr 8, 1980
HeadquartersThousand Oaks, California, United States
SectorBiotechnology
Websiteamgen.com
Last report
Aug 4, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$6.29 / $5.62
+11.97%beat
Revenue / Est. (USD)
10.05B / 9.42B
+6.73%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
9.56B
9.87B
8.62B
10.05B
Cost of goods sold
2.74B
2.68B
2.50B
2.75B
Cost of revenue
2.74B
2.68B
2.50B
2.75B
Research and development expenses
1.90B
2.14B
1.72B
1.87B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.72B
1.95B
1.60B
1.74B
Operating expense
3.55B
4.18B
3.21B
3.73B
Total operating expenses
6.29B
6.85B
5.70B
6.48B
Operating income
3.26B
3.01B
2.91B
3.57B
Other non operating income
181.00M
143.00M
192.00M
145.00M
EBT including unusual items
3.92B
1.51B
2.08B
2.77B
EBT excluding unusual items
2.72B
2.51B
2.37B
3.06B
Income tax expense
705.00M
181.00M
265.00M
393.00M
Effective tax rate
17.98%
11.96%
12.72%
14.20%
Other operating expenses
-71.00M
82.00M
-113.00M
116.00M
Net income
3.22B
1.33B
1.82B
2.38B
Net profit margin
33.65%
13.51%
21.11%
23.62%
Earnings per share
5.64
5.29
5.15
6.29
Interest and investment income
-
408.00M
-
-
Interest expense
-685.00M
-1.06B
-657.00M
-673.00M
Net interest expenses
-685.00M
-653.00M
-657.00M
-673.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
4.57B
4.02B
4.03B
4.69B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps